当前位置: 首页 >> 检索结果
7781. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
作者: Vincent J Nijenhuis.;Jorn Brouwer.;Ronak Delewi.;Renicus S Hermanides.;Wouter Holvoet.;Christophe L F Dubois.;Peter Frambach.;Bernard De Bruyne.;Gert K van Houwelingen.;Jan A S Van Der Heyden.;Petr Toušek.;Frank van der Kley.;Ian Buysschaert.;Carl E Schotborgh.;Bert Ferdinande.;Pim van der Harst.;John Roosen.;Joyce Peper.;Frederick W F Thielen.;Leo Veenstra.;Dean R P P Chan Pin Yin.;Martin J Swaans.;Benno J W M Rensing.;Arnoud W J van 't Hof.;Leo Timmers.;Johannes C Kelder.;Pieter R Stella.;Jan Baan.;Jurriën M Ten Berg.
来源: N Engl J Med. 2020年382卷18期1696-1707页
The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied.
7784. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
作者: C Marc Samama.;Silvy Laporte.;Nadia Rosencher.;Philippe Girard.;Juan Llau.;Patrick Mouret.;William Fisher.;Javier Martínez-Martín.;Daniel Duverger.;Béatrice Deygas.;Emilie Presles.;Michel Cucherat.;Patrick Mismetti.; .
来源: N Engl J Med. 2020年382卷20期1916-1925页
Nonmajor orthopedic surgery of the lower limbs that results in transient reduced mobility places patients at risk for venous thromboembolism. Rivaroxaban may be noninferior to enoxaparin with regard to the prevention of major venous thromboembolism in these patients.
7785. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
作者: Giancarlo Agnelli.;Cecilia Becattini.;Guy Meyer.;Andres Muñoz.;Menno V Huisman.;Jean M Connors.;Alexander Cohen.;Rupert Bauersachs.;Benjamin Brenner.;Adam Torbicki.;Maria R Sueiro.;Catherine Lambert.;Gualberto Gussoni.;Mauro Campanini.;Andrea Fontanella.;Giorgio Vescovo.;Melina Verso.; .
来源: N Engl J Med. 2020年382卷17期1599-1607页
Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is limited by the increased risk of bleeding associated with their use.
7786. Rivaroxaban in Peripheral Artery Disease after Revascularization.
作者: Marc P Bonaca.;Rupert M Bauersachs.;Sonia S Anand.;E Sebastian Debus.;Mark R Nehler.;Manesh R Patel.;Fabrizio Fanelli.;Warren H Capell.;Lihong Diao.;Nicole Jaeger.;Connie N Hess.;Akos F Pap.;John M Kittelson.;Ivan Gudz.;Lajos Mátyás.;Dainis K Krievins.;Rafael Diaz.;Marianne Brodmann.;Eva Muehlhofer.;Lloyd P Haskell.;Scott D Berkowitz.;William R Hiatt.
来源: N Engl J Med. 2020年382卷21期1994-2004页
Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this context are uncertain.
7787. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
作者: Paul W Armstrong.;Burkert Pieske.;Kevin J Anstrom.;Justin Ezekowitz.;Adrian F Hernandez.;Javed Butler.;Carolyn S P Lam.;Piotr Ponikowski.;Adriaan A Voors.;Gang Jia.;Steven E McNulty.;Mahesh J Patel.;Lothar Roessig.;Joerg Koglin.;Christopher M O'Connor.; .
来源: N Engl J Med. 2020年382卷20期1883-1893页
The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.
7788. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.
作者: Temet M McMichael.;Dustin W Currie.;Shauna Clark.;Sargis Pogosjans.;Meagan Kay.;Noah G Schwartz.;James Lewis.;Atar Baer.;Vance Kawakami.;Margaret D Lukoff.;Jessica Ferro.;Claire Brostrom-Smith.;Thomas D Rea.;Michael R Sayre.;Francis X Riedo.;Denny Russell.;Brian Hiatt.;Patricia Montgomery.;Agam K Rao.;Eric J Chow.;Farrell Tobolowsky.;Michael J Hughes.;Ana C Bardossy.;Lisa P Oakley.;Jesica R Jacobs.;Nimalie D Stone.;Sujan C Reddy.;John A Jernigan.;Margaret A Honein.;Thomas A Clark.;Jeffrey S Duchin.; .
来源: N Engl J Med. 2020年382卷21期2005-2011页
Long-term care facilities are high-risk settings for severe outcomes from outbreaks of Covid-19, owing to both the advanced age and frequent chronic underlying health conditions of the residents and the movement of health care personnel among facilities in a region.
|